CollPlant Biotechnologies (NASDAQ:CLGN) Shares Down 0.4% – Here’s Why

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) shares were down 0.4% on Friday . The company traded as low as $0.54 and last traded at $0.5650. Approximately 130,469 shares traded hands during mid-day trading, a decline of 25% from the average daily volume of 173,961 shares. The stock had previously closed at $0.5670.

Analysts Set New Price Targets

Several research analysts have commented on the stock. D. Boral Capital cut shares of CollPlant Biotechnologies from a “buy” rating to a “hold” rating in a report on Friday, February 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of CollPlant Biotechnologies in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, CollPlant Biotechnologies currently has an average rating of “Hold” and an average target price of $11.50.

CollPlant Biotechnologies Stock Down 0.4%

The firm has a market capitalization of $7.23 million, a PE ratio of -0.55 and a beta of 2.28. The business’s 50-day moving average price is $1.27 and its 200-day moving average price is $1.95.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its quarterly earnings data on Wednesday, November 26th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.65). CollPlant Biotechnologies had a negative net margin of 491.31% and a negative return on equity of 102.00%. The company had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $16.52 million. On average, analysts anticipate that CollPlant Biotechnologies Ltd. Sponsored ADR will post -1.44 EPS for the current fiscal year.

Institutional Trading of CollPlant Biotechnologies

A number of institutional investors have recently bought and sold shares of the company. AMH Equity Ltd grew its stake in CollPlant Biotechnologies by 24.3% in the third quarter. AMH Equity Ltd now owns 200,000 shares of the company’s stock valued at $538,000 after purchasing an additional 39,151 shares in the last quarter. Pinnacle Associates Ltd. lifted its holdings in shares of CollPlant Biotechnologies by 3.7% during the 2nd quarter. Pinnacle Associates Ltd. now owns 507,193 shares of the company’s stock valued at $690,000 after buying an additional 18,000 shares during the last quarter. Finally, Villere ST Denis J & Co. LLC lifted its holdings in shares of CollPlant Biotechnologies by 3.2% during the 4th quarter. Villere ST Denis J & Co. LLC now owns 607,300 shares of the company’s stock valued at $850,000 after buying an additional 18,583 shares during the last quarter. Institutional investors and hedge funds own 21.69% of the company’s stock.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.